Biocon Ltd
India's technology spending is projected to reach approximately US$ 54.5 billion (Rs. 4.49 trillion) by 2027, making it the highest in the Asia Pacific (APAC) region.
Biocon is Asia's premier biopharmaceutical company that is driven by the vision to make a difference in global healthcare through improved access to high-quality, life-saving biotherapeutics by making them affordable for patients across the world. Biocon is among the few companies globally to have received approvals for its biosimilars from developed countries like the U.S., EU, Australia, and Japan. Its credibility as a serious player in the biosimilar sector was first established with the Japanese approval for Insulin Glargine. The credibility was enhanced when Biocon, along with partner Mylan, became the first global company to get biosimilar Trastuzumab and Pegfilgrastim approved in the US in 2017 and 2018, respectively. It was also among the first few to receive Insulin Glargine approval in Europe and Australia for Insulin Glargine, both in partnership with Mylan. It also established its presence in key emerging markets through safe, effective, and high-quality biosimilars including recombinant human insulin.
- Total revenue of Rs. 3,856 crore (US$ 445.5 million) in Q3 FY25.
- Started a clinical trial in India to study Itolizumab in treating moderate to severe patients with COVID-19 complications.
- Is the sixth-largest manufacturer of sodium bicarbonate worldwide.
- Expanded commercial footprint of key biosimilars, including Pegfilgrastim (Australia, Canada), Trastuzumab (the US, Australia, Canada) and Insulin Glargine (Australia) through its partner Mylan.
Biocon
| Year | Milestone |
|---|---|
| 2025 |
On January 31, 2025, Biocon Ltd. announced it has completed the Rs. 555 crore (US$ 64.1 million) acquisition of a 1.5% stake in Biocon Biologics Ltd., raising its total holding to 90.2%. On January 27, 2025, Biocon Limited, achieved an improved S&P Global ESG Score of 69 in 2024, up 6 points from 2023, placing it in the 98th percentile among global biotech peers. |
| 2024 |
On December 11, 2024, Biocon Biologics Limited, a subsidiary of Biocon Limited, announced that it has once again been recognized as an Asia IP Elite for 2024 by IAM (Intellectual Asset Management), the world's leading Intellectual Property (IP) publication. This is the eighth consecutive year for Biocon and subsequently its subsidiary Biocon Biologics to make it to this prestigious list. In May 2024, Biocon Limited announced the signing of an exclusive licensing and supply agreement with Handok, a specialty pharmaceutical company in South Korea, for the commercialization of its vertically integrated, complex drug product, Synthetic Liraglutide. In March 2024, Biocon Biologics Limited, a subsidiary of Biocon Limited, entered into a strategic commercial collaboration with Eris Lifesciences to broaden patient access to its portfolio of Metabolics, Oncology, and Critical Care products across India. |
| 2023 |
In December 2023, Biocon Biologics Ltd., inked a Distribution Agreement with Sandoz, granting exclusive rights to market and distribute "Adalimumab BS for subcutaneous injection [FKB]" in Japan. In December 2023, Bicara Therapeutics, an associate of Biocon in the US, raised US$ 165 million co-led by Braidwell and TPG. In September 2023, Biocon Limited announced the acquisition of a manufacturing facility of Eywa Pharma Inc. In August 2023, Biocon Foundation and Shakti Sustainable Energy Foundation organised Cities and Climate Action Workshop. In July 2023, Biocon Biologics Ltd (BBL) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of YESAFILI®, an aflibercept biosimilar. Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd. announced that the company has completed the integration of the acquired biosimilars business in over 70 countries in Emerging Markets effective July 1, 2023, increasing the scale and scope of its business. Biocon Biologics Wins the Asia-Pacific Bioprocessing Excellence Awards (ABEA) 2023: Bioprocessing Excellence in South Asia Award. |
| 2022 |
In October 2022, the prestigious US-based Science magazine named Biocon as one of the Top 10 Employers in the global biotech, pharma, and biopharma sector. In February 2022, Biocon announced the acquisition of Viatris Inc.’s biosimilar assets for US$ 3.34 billion. |
| 2021 |
Biocon Biologics Limited (BBL) and Serum Institute Life Sciences Private Limited (SILS) announced a strategic alliance to develop antibodies for infectious diseases such as dengue, HIV and others. In February 2021, Biocon Biologics Ltd., a subsidiary of Biocon Ltd., partnered with The International Diabetes Federation (IDF) as the first biosimilar insulin company to promote and support IDF’s Core Mission initiative and activities. In January 2021, Biocon Biologics Ltd., a subsidiary of Biocon Ltd., received Rs. 555 crore (US$ 75 Million) capital injection from a primary equity investment firm ADQ. |
| 2020 |
In November 2020, Biocon Biologics received a US$ 150 million capital injection from Goldman Sachs. On July 13, 2020, Biocon got approval from the Drugs Controller General of India (DCGI) to launch the biologic drug Itolizumab for the treatment of moderate to severe COVID-19 patients. |
| 2019 |
With the subsidiary of China Medical System Holdings Ltd. (CMS), Biocon signed the license and supply agreement for three generic formulation products in Greater China. Mylan and Biocon Launch First Trastuzumab Biosimilar, Ogivri™, in Australia. |
| 2018 |
Sandoz Biosimilars collaboration signed. The U.S. FDA approves Fulphila™, co-developed by Biocon and Mylan and Therapeutic Goods Administration, Australia-approved biosimilar Insulin Glargine, Semglee™ 100 IU/mL 3 mL prefilled pen. |
| 2017 |
Launched Ogrivi™, the first biosimilar of trastuzumab approved by US FDA. |
| 2016 |
The Insulin Glargine pen for people with diabetes was launched in Japan as the first biosimilar from India. |
| 2014 |
Biocon introduced CANMAb™ - Trastuzumab for Treating Breast Cancer in India. |
| 2011 |
Biocon launched INSUPen®, a convenient and affordable reusable insulin delivery device. |
| 2006 |
India’s first indigenously produced novel monoclonal antibody, Nimotuzumab, for head & neck cancer, launched. |
| 2002 |
Clinigene's clinical laboratory was the first in India to receive CAP accreditation. |
| 2000 |
Biocon commissioned its first fully automated submerged fermentation plant to produce speciality pharmaceuticals and established Clinigene, India's first Clinical Research Organisation (CRO) to pursue clinical research and development. |
| 1997 |
Biocon spearheaded initiatives in human healthcare through a dedicated manufacturing facility. |
| 1993 |
Biocon scaled up its in-house research programme. |
| 1979 |
Biocon was the first Indian company to manufacture and export enzymes to the USA and Europe. |
| 1978 |
Biocon India was incorporated as a joint venture (JV) between Biocon Biochemicals Ltd. of Ireland and an Indian entrepreneur, Mr Kiran Mazumdar-Shaw. |
Partners
